U.S. Markets closed

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1500-0.0300 (-2.54%)
At close: 4:00PM EDT

Soleno Therapeutics, Inc.

203 Redwood Shores Parkway
Suite 500
Redwood City, CA 94065
United States
650 213 8444
http://soleno.life

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees17

Key Executives

NameTitlePayExercisedYear Born
Dr. Anish BhatnagarPres, CEO, COO & Director552.25kN/A1970
Mr. James H. MacKanessCFO, Principal Financial & Accounting OfficerN/AN/A1964
Mr. Anthony WondkaSr. VP & GMN/AN/A1962
Dr. Neil M. Cowen M.B.A., Ph.D., MBASr. VP of Drug Devel.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Corporate Governance

Soleno Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.